Lucence raises $20 million Series A for its non-invasive cancer screening technology
0Reported today on TechCrunch
For the full article visit: https://tcrn.ch/334oZqi
Lucence raises $20 million Series A for its non-invasive cancer screening technology
Lucence Diagnostics, a genomic medicine startup that develops non-invasive tests for cancer screening, announced today that it has raised a $20 million Series A led by IHH Healthcare, one of the world's largest integrated private healthcare groups. Other participants included SGInnovate and returning investors Heliconia Capital (a subsidiary of Temasek Holdings), Lim Kaling and Koh Boon Hwee.
The round will be used for scaling Lucence's labs, hiring and making its products commercially available to more patients in Asia and North America.
The funding will also support two prospective clinical trials. One will focus on its technology's sensitivity to actionable variables in late-stage cancer patients, while the other will evaluate its use for early-stage detection in several types of cancer, including lung, colorectal, breast and pancreatic. Lucence is currently designing a study that will involve 100,000 participants to validate its early-stage detection test. It will recruit its first patient in the middle of next year and launch in the United States and Asia.
Together with its seed funding, this round brings Lucence's total raised so far to $29.2 million.
Lucence's tests are currently used by physicians in Southeast Asia and Hong Kong, and it plans to expand further in North America and East Asia. Its lab in Singapore has received both CLIA certification and CAP accreditation, which means its tests can be used by doctors and patients in the United States. It is also currently building a lab in the Bay Area to decrease turnaround times for patients.
Headquartered in Singapore, with offices in San Francisco, Hong Kong and Suzhou, China, Lucence was founde